

Jerzy Åwierkot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8907257/publications.pdf>

Version: 2024-02-01

44
papers

792
citations

516710

16
h-index

552781

26
g-index

45
all docs

45
docs citations

45
times ranked

1240
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. <i>RMD Open</i> , 2022, 8, e002012.	3.8	50
2	Usefulness of noninvasive diagnostic procedures for assessment of methotrexate hepatotoxicity in patients with rheumatoid arthritis. <i>Rheumatology International</i> , 2022, 42, 631-638.	3.0	5
3	Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity. <i>Vaccines</i> , 2022, 10, 710.	4.4	9
4	The assessment of the risk of COVID-19 infection and its course in the medical staff of a COVID-only and a non-COVID hospital. <i>Advances in Clinical and Experimental Medicine</i> , 2022, 31, 0-0.	1.4	1
5	Searching for New Genetic Biomarkers of Axial Spondyloarthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 2912.	2.4	2
6	Relationship Between Interleukin-6 174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 157-166.	0.7	3
7	IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 631603.	4.8	18
8	Disease Differentiation and Monitoring of Anti-TNF Treatment in Rheumatoid Arthritis and Spondyloarthropathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7389.	4.1	3
9	Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors. <i>Disease Markers</i> , 2021, 2021, 1-15.	1.3	4
10	Shared epitope and polymorphism of MICA and NKG2D encoding genes in Greek and Polish patients with rheumatoid arthritis. <i>Central-European Journal of Immunology</i> , 2021, 46, 92-98.	1.2	7
11	Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts. <i>Frontiers in Immunology</i> , 2021, 12, 672255.	4.8	6
12	Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis. <i>Mediators of Inflammation</i> , 2021, 2021, 1-9.	3.0	5
13	Periodontal disease and influence of periodontal treatment on disease activity in patients with rheumatoid arthritis and spondyloarthritis. <i>Rheumatology International</i> , 2020, 40, 455-463.	3.0	24
14	Primary Immunodeficiencies: Diseases of Children and Adults  A Review. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1289, 37-54.	1.6	10
15	Polymorphisms within the RANK and RANKL Encoding Genes in Patients with Rheumatoid Arthritis: Association with Disease Progression and Effectiveness of the Biological Treatment. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 24.	2.3	6
16	Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2020, 20, 760-769.	2.0	10
17	Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients. <i>Drugs in Context</i> , 2020, 9, 1-15.	2.2	6
18	Ormonds disease accompanied by ankylosing spondylitis  a case report. <i>Pomeranian Journal of Life Sciences</i> , 2020, 66, 16-20.	0.1	0

#	ARTICLE	IF	CITATIONS
19	Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. Archives of Medical Science, 2019, 15, 134-140.	0.9	30
20	Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 2473-2481.	2.2	26
21	ABO411...TNF ALPHA INHIBITORS INFLUENCE THE CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITIS PATIENTS. , 2019, , .		0
22	Autoantibody and metalloproteinase activity in early arthritis. Clinical Rheumatology, 2019, 38, 827-834.	2.2	4
23	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. Pharmacogenomics Journal, 2018, 18, 539-545.	2.0	14
24	The importance of ultrasound examination in early arthritis. Reumatologia, 2018, 56, 354-361.	1.1	7
25	Biosimilar switching “ current state of knowledge. Reumatologia, 2018, 56, 234-242.	1.1	33
26	The role of diet in rheumatoid arthritis. Reumatologia, 2018, 56, 259-267.	1.1	42
27	Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes, 2018, 9, 64.	2.4	20
28	Addendum: Iwaszko et al., Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes 2018, 9, 64. Genes, 2018, 9, 94.	2.4	0
29	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. Scientific Reports, 2018, 8, 7342.	3.3	18
30	Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF- Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2018, 66, 389-397.	2.3	39
31	Methotrexate treatment for rheumatoid arthritis in Poland: Retrospective analysis of patients in routine clinical practice. Reumatologia, 2018, 56, 3-9.	1.1	5
32	The role of microRNA-5196 in the pathogenesis of systemic sclerosis. European Journal of Clinical Investigation, 2017, 47, 555-564.	3.4	25
33	Results from Polish Spondyloarthritis Initiative registry (PolSPI) “ methodology and data from “ the first year of observation. Reumatologia, 2017, 2, 59-64.	1.1	0
34	Polymorphisms within Genes Involved in Regulation of the NF-B Pathway in Patients with Rheumatoid Arthritis. International Journal of Molecular Sciences, 2017, 18, 1432.	4.1	29
35	Significance of Polymorphism and Expression of miR-146a and NFkB1 Genetic Variants in Patients with Rheumatoid Arthritis. Archivum Immunologiae Et Therapiae Experimentalis, 2016, 64, 131-136.	2.3	63
36	Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment. Joint Bone Spine, 2016, 83, 75-79.	1.6	10

#	ARTICLE	IF	CITATIONS
37	Application of ¹ H NMR-based serum metabolomic studies for monitoring female patients with rheumatoid arthritis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 117, 544-550.	2.8	50
38	The Activity of JAK/STAT and NF- κ B in Patients with Rheumatoid Arthritis. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 709-717.	1.4	31
39	Cytokine profiles in axial spondyloarthritis. <i>Reumatologia</i> , 2015, 53, 9-13.	1.1	15
40	IL-17A, IL-17F and IL-23R Gene Polymorphisms in Polish Patients with Rheumatoid Arthritis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 215-221.	2.3	63
41	Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2015, 63, 397-404.	2.3	36
42	Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2015, 82, 94-99.	1.6	42
43	Activity of JAK/STAT and NF- κ B in patients with axial spondyloarthritis. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2015, 69, 1291-1298.	0.1	8
44	Significance of association of HLA-C and HLA-E with psoriatic arthritis. <i>Human Immunology</i> , 2014, 75, 1188-1191.	2.4	13